GlassScriptPhysician profile
Tamer Alsebai
NPI 1528091071
$5,559.66
in general payments reported to CMS, 2019-2025
22 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $233 · 2021: $205 · 2022: $540 · 2023: $1,321 · 2024: $1,941 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,482.16 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,273.29 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Glaxosmithkline, LLC. | $548.45 | 2021-2025 | Benlysta |
| Pfizer INC. | $352.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $271.99 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.71 | 2022-2024 | Ofev, Cyltezo |
| Ucb, INC. | $234.04 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $202.34 | 2022-2025 | Acthar |
| Lilly USA, LLC | $139.92 | 2019-2024 | Taltz |
| Janssen Scientific Affairs, LLC | $128.84 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.74 | 2019-2024 | |
| Genentech USA, INC. | $82.89 | 2023-2025 | Actemra, Gazyva |
| Janssen Biotech, INC. | $57.68 | 2019-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $54.08 | 2024 | Lupkynis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51.66 | 2023-2024 | Saphnelo |
| Radius Health, INC. | $49.18 | 2019-2024 | Tymlos |
| Sobi, INC | $46.92 | 2025 | |
| Horizon Therapeutics Plc | $46.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.29 | 2022 | |
| Merck Sharp & Dohme LLC | $22.90 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $17.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamer Alsebai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.